Our results corroborate the notion that high-dose GCs exhibit their diverging potency in autoimmune diseases by preferentially targeting particular prone cytokine pathways and leukocyte subsets (39) — notably, Th1/IFN-γ driven disorders. This evidence concerns the gene IFNG and autoimmune disease.